HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China

详细信息    查看全文

• 作者：Zheng Wei (1)
  Shanhua Zou (1)
  Feng Li (1)
  Zhixiang Cheng (1)
  Junmin Li (2)
  Jianmin Wang (3)
  Chun Wang (4)
  Fangyuan Chen (5)
  Junning Cao (6)
  Yunfeng Cheng (1) (7)
  
• 关键词：Diffuse large B cell lymphoma ; Prognostication ; HBsAg
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：31
• 期：3
• 全文大小：351 KB
• 作者单位：Zheng Wei (1)
  Shanhua Zou (1)
  Feng Li (1)
  Zhixiang Cheng (1)
  Junmin Li (2)
  Jianmin Wang (3)
  Chun Wang (4)
  Fangyuan Chen (5)
  Junning Cao (6)
  Yunfeng Cheng (1) (7)
  
  1. Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China
  2. Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  3. Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
  4. Department of Hematology, Shanghai First People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  5. Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  6. Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China
  7. Biomedical Research Center, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China
  
• ISSN：1559-131X

文摘

This study mainly focused on the impact of Hepatitis B virus (HBV) infection on the prognosis of diffuse large B cell lymphoma (DLBCL) patients in rituximab era, using a Cox regression model to ascertain the prediction value of the serum HBV marker in survivals. Three hundred and eighty four DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (R-CHOP-like regimens) or CHOP-like regimens were included. Progression-free survival (PFS) and overall survival (OS) of the patients have or have not received rituximab were analyzed separately. In the CHOP group, HBV infection has not been found a profound impact on the survivals. In the R-CHOP group, PFS and OS were inferior in HBsAg-positive patients (p?=?0.031 and p?=?0.006, respectively); after adjusting for International Prognostic Index parameters, HBsAg is an independent unfavorable factor for both PFS (RR?=?2.492) and OS (RR?=?2.589).